Iron Carboxymaltose

ApprovedSmall molecule

HHospital de Clinicas de Porto Alegre

Iron Carboxymaltose is one of 135 small molecule programs targeting Fatigue. It is currently in Approved.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Iron Deficiency AnemiaActive, not recruiting

HypophosphatemiaActive, not recruiting

AnemiaActive, not recruiting

Heart FailureActive, not recruiting

Liver TransplantApproved

Active, not recruiting

Iron Deficiency AnemiaPhase 1

Active, not recruiting

HypophosphatemiaApproved

Active, not recruiting

AnemiaApproved

Active, not recruiting

Heart FailurePhase 3

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Iron Carboxymaltose

HHospital de Clinicas de Porto Alegre

Approved

3 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Activase

Zemplar

Zoloft

VViatris Specialty LLC

Preclinical

2 7

Coumadin

AAbbott

Preclinical

1 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 9

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Oraverse

LLife Extension Foundation Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Heart Failure

NCT06434025

Clinical

Trials by Indication[1]

Heart Failure3 trials

New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure

Unknown status·HHospital Universitari de Bellvitge··NCT05000853·210 enrolled

IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency

Not yet recruiting·HHospital de Clinicas de Porto Alegre·Phase 3·NCT06434025·99 enrolled

Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency

Withdrawn·TTel-Aviv Sourasky Medical Center·Phase 4·NCT03042130

Anemia2 trials

Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women

Completed·—·Phase 4·NCT06911034·60 enrolled

Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia

Completed·UUniversity Medical Centre Ljubljana·Phase 3·NCT03957057·300 enrolled

Fatigue1 trial

Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue

Unknown status·—·Phase 4·NCT03305705·20 enrolled

Hypophosphatemia1 trial

IV Iron-induced Hypophosphatemia After RYGB

Recruiting·LLucie Favre·Phase 4·NCT06350955·94 enrolled

Iron deficiency anemia1 trial

EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY

Completed·DDr Salaha Azam·Phase 1·NCT07384663·112 enrolled

4 more indications

Liver Transplant1 trial

Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation

Unknown status·MMedical University of Vienna·Phase 4·NCT04475887·60 enrolled

Gastric1 trial

Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass

Completed·RRijnstate Hospital·Phase 4·NCT02271997·120 enrolled

Menopausal Women1 trial

Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women

Completed·UUniversity of Zurich·Phase 4·NCT01374776·24 enrolled

Donor1 trial

Iron Substitution in Blood Donors

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT01519830·405 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Iron Carboxymaltose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iron Carboxymaltose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iron Carboxymaltose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital de Clinicas de Porto Alegre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHospital de Clinicas de Porto Alegre

Iron Carboxymaltose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Heart Failure3 trials

Anemia2 trials

Fatigue1 trial

Hypophosphatemia1 trial

Iron deficiency anemia1 trial

Liver Transplant1 trial

Gastric1 trial

Menopausal Women1 trial

Donor1 trial

References

Drug Info

Quick Facts

Related News